The adaptable major histocompatibility complex (MHC) fold: Structure and function of nonclassical and mhc class I-like molecules

Annual Review of Immunology

Volumn 31, Issue , 2013, Pages 529-561

  Adams, Erin J ^a   Luoma, Adrienne M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Antigen presentation; Evolution; Homeostasis; NK receptors; T cell receptor

Indexed keywords

CD1B ANTIGEN; CD1C ANTIGEN; CD1D ANTIGEN; CD8 ANTIGEN; CD94 ANTIGEN; FC RECEPTOR; GAMMA INTERFERON; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA E ANTIGEN; HLA G ANTIGEN; INTERLEUKIN 17; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL KILLER CELL RECEPTOR NKG2D; T6 ANTIGEN;

ALPHA HELIX; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN STRUCTURE; BETA SHEET; CELL LINEAGE; CELL MIGRATION; CELL SURFACE; CONFORMATIONAL TRANSITION; CROSS REACTION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; EMBRYO DEVELOPMENT; ENDOCYTOSIS; ENDOPLASMIC RETICULUM; HUMAN; HYDROPHOBICITY; IMMUNOMODULATION; IMMUNOREGULATION; INNATE IMMUNITY; IRON TRANSPORT; LIPID METABOLISM; LIPOLYSIS; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PROTEIN INTERACTION; REVIEW; THYMOCYTE;

ANIMALS; ANTIGEN PRESENTATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-G ANTIGENS; HUMANS; IMMUNITY, INNATE; MICE; PROTEIN FOLDING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84875513590     PISSN: 07320582     EISSN: 15453278     Source Type: Book Series    
DOI: 10.1146/annurev-immunol-032712-095912     Document Type: Review

References (158)

1. Bjorkman PJ, Parham P. 1990. Structure, function, and diversity of class I major histocompatibility complex molecules. Annu. Rev. Biochem. 59:253-888
2. Rodgers JR, Cook RG. 2005. MHC class Ib molecules bridge innate and acquired immunity. Nat. Rev. Immunol. 5:459-711
3. Olson R, Dulac C, Bjorkman PJ. 2006. MHC homologs in the nervous system -they haven't lost their groove. Curr. Opin. Neurobiol. 16:351-577
4. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. 1987. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 329:506-122
5. Hoare HL, Sullivan LC, Pietra G, Clements CS, Lee EJ, et al. 2006. Structural basis for a major histocompatibility complex class Ib-restricted T cell response. Nat. Immunol. 7:256-644
6. Kaiser BK, Pizarro JC, Kerns J, Strong RK. 2008. Structural basis for NKG2A/CD94 recognition of HLA-E. Proc. Natl. Acad. Sci. USA 105:6696-7011
7. Petrie EJ, Clements CS, Lin J, Sullivan LC, Johnson D, et al. 2008. CD94-NKG2A recognition of human leukocyte antigen (HLA)-E bound to an HLA class I leader sequence. J. Exp. Med. 205:725-355
8. Hoare HL, Sullivan LC, Clements CS, Ely LK, Beddoe T, et al. 2008. Subtle changes in peptide conformation profoundly affect recognition of the non-classical MHC class I molecule HLA-E by the CD94-NKG2 natural killer cell receptors. J. Mol. Biol. 377:1297-3033
9. O'Callaghan CA, Tormo J, Willcox BE, Braud VM, Jakobsen BK, et al. 1998. Structural features impose tight peptide binding specificity in the nonclassical MHC molecule HLA-E. Mol. Cell 1:531-411
10. Strong RK, Holmes MA, Li P, Braun L, Lee N, Geraghty DE. 2003. HLA-E allelic variants. Correlating differential expression, peptide affinities, crystal structures, and thermal stabilities. J. Biol. Chem. 278:5082-900
11. Shiroishi M, Kuroki K, Ose T, Rasubala L, Shiratori I, et al. 2006. Efficient leukocyte Ig-like receptor signaling and crystal structure of disulfide-linked HLA-G dimer. J. Biol. Chem. 281:10439-477
12. Clements CS, Kjer-Nielsen L, Kostenko L, Hoare HL, Dunstone MA, et al. 2005. Crystal structure of HLA-G: a nonclassical MHC class I molecule expressed at the fetal-maternal interface. Proc. Natl. Acad. Sci. USA 102:3360-655
13. Shiroishi M, Kuroki K, Rasubala L, Tsumoto K, Kumagai I, et al. 2006. Structural basis for recognition of the nonclassical MHC molecule HLA-G by the leukocyte Ig-like receptor B2 (LILRB2/LIR2/ILT4/CD85d). Proc. Natl. Acad. Sci. USA 103:16412-177
14. Walpole NG, Kjer-Nielsen L, Kostenko L, McCluskey J, Brooks AG, et al. 2010. The structure and stability of the monomorphic HLA-G are influenced by the nature of the bound peptide. J. Mol. Biol. 397:467-800
15. Wang CR, Castano AR, Peterson PA, Slaughter C, Lindahl KF, Deisenhofer J. 1995. Nonclassical binding of formylated peptide in crystal structure of the MHC class Ib molecule H2-M3. Cell 82:655-644
16. Zeng L, Sullivan LC, Vivian JP, Walpole NG, Harpur CM, et al. 2012. A structural basis for antigen presentation by the MHC class Ib molecule, Qa-1b. J. Immunol. 188:302-100
17. He X, Tabaczewski P, Ho J, Stroynowski I, Garcia KC. 2001. Promiscuous antigen presentation by the nonclassical MHC Ib Qa-2 is enabled by a shallow, hydrophobic groove and self-stabilized peptide conformation. Structure 9:1213-244
18. Joly E, Rouillon V. 2006. The orthology of HLA-E and H2-Qa1 is hidden by their concerted evolution with other MHC class I molecules. Biol. Direct. 1:22
19. Comiskey M, Goldstein CY, De Fazio SR, MammolentiM, Newmark JA, Warner CM. 2003. Evidence that HLA-G is the functional homolog of mouse Qa-2, the Ped gene product. Hum. Immunol. 64:999-10044
20. Braud V, Jones EY, McMichael A. 1997. The human major histocompatibility complex class Ibmolecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9. Eur. J. Immunol. 27:1164-699
21. Aldrich CJ, DeCloux A, Woods AS, Cotter RJ, Soloski MJ, Forman J. 1994. Identification of a Tapdependent leader peptide recognized by alloreactive T cells specific for a class Ib antigen. Cell 79:649-588
22. Braud VM, Allan DS, O'Callaghan CA, Soderstrom K, D'Andrea A, et al. 1998. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391:795-999
23. Vance RE, Kraft JR, Altman JD, Jensen PE, Raulet DH. 1998. Mouse CD94/NKG2A is a natural killer cell receptor for the nonclassical major histocompatibility complex (MHC) class I molecule Qa-1(b). J. Exp. Med. 188:1841-488
24. Pietra G, Romagnani C, Moretta L, Mingari MC. 2009. HLA-E and HLA-E-bound peptides: recognition by subsets of NK and T cells. Curr. Pharm. Des. 15:3336-444
25. Sullivan LC, Hoare HL, McCluskey J, Rossjohn J, Brooks AG. 2006. A structural perspective on MHC class Ib molecules in adaptive immunity. Trends Immunol. 27:413-200
26. Allan DS, Colonna M, Lanier LL, Churakova TD, Abrams JS, et al. 1999. Tetrameric complexes of human histocompatibility leukocyte antigen (HLA)-G bind to peripheral blood myelomonocytic cells. J. Exp. Med. 189:1149-566
27. Ponte M, Cantoni C, Biassoni R, Tradori-Cappai A, Bentivoglio G, et al. 1999. Inhibitory receptors sensing HLA-G1 molecules in pregnancy: decidua-associated natural killer cells express LIR-1 and CD94/NKG2A and acquire p49, an HLA-G1-specific receptor. Proc. Natl. Acad. Sci. USA 96:5674-799
28. Rajagopalan S, Long EO. 1999. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J. Exp. Med. 189:1093-1000
29. Gomes AQ, Correia DV, Silva-Santos B. 2007. Non-classical major histocompatibility complex proteins as determinants of tumour immunosurveillance. EMBO Rep. 8:1024-300
30. Lee N, Malacko AR, Ishitani A, Chen MC, Bajorath J, et al. 1995. The membrane-bound and soluble forms of HLA-G bind identical sets of endogenous peptides but differ with respect to TAP association. Immunity 3:591-6000
31. Joyce S, Tabaczewski P, Angeletti RH, Nathenson SG, Stroynowski I. 1994. A nonpolymorphic major histocompatibility complex class Ib molecule binds a large array of diverse self-peptides. J. Exp. Med. 179:579-888
32. Rotzschke O, Falk K, Stevanovic S, Grahovac B, Soloski MJ, et al. 1993. Qa-2 molecules are peptide receptors of higher stringency than ordinary class I molecules. Nature 361:642-444
33. Tabaczewski P, Chiang E, Henson M, Stroynowski I. 1997. Alternative peptide binding motifs of Qa-2 class Ib molecules define rules for binding of self and nonself peptides. J. Immunol. 159:2771-811
34. Ishitani A, Sageshima N, Lee N, Dorofeeva N, Hatake K, et al. 2003. Protein expression and peptide binding suggest unique and interacting functional roles for HLA-E, F, and G in maternal-placental immune recognition. J. Immunol. 171:1376-844
35. Munz C, Stevanovic S, Rammensee HG. 1999. Peptide presentation and NK inhibition by HLA-G. J. Reprod. Immunol. 43:139-555
36. Willcox BE, Thomas LM, Bjorkman PJ. 2003. Crystal structure of HLA-A2 bound to LIR-1, a host and viral major histocompatibility complex receptor. Nat. Immunol. 4:913-199
37. Boyson JE, Erskine R, WhitmanMC, Chiu M, Lau JM, et al. 2002. Disulfide bond-mediated dimerization of HLA-G on the cell surface. Proc. Natl. Acad. Sci. USA 99:16180-855
38. Gonen-Gross T, Achdout H, Gazit R, Hanna J, Mizrahi S, et al. 2003. Complexes of HLA-G protein on the cell surface are important for leukocyte Ig-like receptor-1 function. J. Immunol. 171:1343-511
39. YanWH, Fan LA. 2005. ResiduesMet76 and Gln79 in HLA-Gα1 domain involved in KIR2DL4 recognition. Cell Res. 15:176-822
40. Shawar SM, Cook RG, Rodgers JR, Rich RR. 1990. Specialized functions of MHC class I molecules. I. An N-formyl peptide receptor is required for construction of the class I antigen Mta. J. Exp. Med. 171:897-9122
41. Smith GP, Dabhi VM, Pamer EG, Lindahl KF. 1994. Peptide presentation by the MHC class Ib molecule, H2-M3. Int. Immunol. 6:1917-266
42. Vyas JM, Rodgers JR, Rich RR. 1995. H-2M3a violates the paradigm for major histocompatibility complex class I peptide binding. J. Exp. Med. 181:1817-255
43. Lenz LL, BevanMJ. 1997.CTLresponses toH2-M3-restricted Listeria epitopes. Immunol. Rev. 158:115-211
44. Gulden PH, Fischer P 3rd, Sherman NE, WangW, Engelhard VH, et al. 1996. A Listeria monocytogenes pentapeptide is presented to cytolytic T lymphocytes by the H2-M3 MHC class Ib molecule. Immunity 5:73-799
45. Leishman AJ, Naidenko OV, Attinger A, Koning F, Lena CJ, et al. 2001. T cell responses modulated through interaction between CD8ααand the nonclassicalMHCclass I molecule, TL. Science 294:1936-399
46. Huang Y, Park Y, Wang-Zhu Y, Larange A, Arens R, et al. 2011. Mucosal memory CD8-T cells are selected in the periphery by an MHC class I molecule. Nat. Immunol. 12:1086-955
47. Chien YH, Konigshofer Y. 2007. Antigen recognition by γδT cells. Immunol. Rev. 215:46-588
48. Hershberg R, Eghtesady P, Sydora B, Brorson K, Cheroutre H, et al. 1990. Expression of the thymus leukemia antigen in mouse intestinal epithelium. Proc. Natl. Acad. Sci. USA 87:9727-311
49. Wu M, van Kaer L, Itohara S, Tonegawa S. 1991. Highly restricted expression of the thymus leukemia antigens on intestinal epithelial cells. J. Exp. Med. 174:213-188
50. Madakamutil LT, Christen U, Lena CJ, Wang-Zhu Y, Attinger A, et al. 2004.CD8αα-mediated survival and differentiation of CD8 memory T cell precursors. Science 304:590-933
51. Liu Y, Xiong Y, Naidenko OV, Liu JH, Zhang R, et al. 2003. The crystal structure of a TL/CD8αα complex at 2.1 ̊A resolution: implications for modulation of T cell activation and memory. Immunity 18:205-155
52. AdamsEJ, Chien YH, Garcia KC. 2005. Structure of a γδTcell receptor in complex with the nonclassical MHC T22. Science 308:227-311
53. Adams EJ, Strop P, Shin S, Chien YH, Garcia KC. 2008. An autonomous CDR3δ is sufficient for recognition of the nonclassical MHC class I molecules T10 and T22 by γδ T cells. Nat. Immunol. 9:777-844
54. Boulanger LM. 2004.MHCclass I in activity-dependent structural and functional plasticity. Neuron Glia Biol. 1:283-899
55. WingrenC, Crowley MP, DeganoM, Chien Y, Wilson IA. 2000. Crystal structure of a γδTcell receptor ligand T22: a truncated MHC-like fold. Science 287:310-144
56. Jensen KD, Su X, Shin S, Li L, Youssef S, et al. 2008. Thymic selection determines γδ T cell effector fate: antigen-naive cells make interleukin-17 and antigen-experienced cells make interferon γ. Immunity 29:90-1000
57. Shin S, El-Diwany R, Schaffert S, Adams EJ, Garcia KC, et al. 2005. Antigen recognition determinants of γδT cell receptors. Science 308:252-555
58. Sandstrom A, ScharfL, McRae G, Hawk AJ, Meredith SC, Adams EJ. 2012. γδTcell receptors recognize the non-classical major histocompatibility complex (MHC) molecule T22 via conserved anchor residues in a MHC peptide-like fashion. J. Biol. Chem. 287:6035-433
59. OlsonR, Huey-Tubman KE, Dulac C, Bjorkman PJ. 2005. Structure of a pheromone receptor-associated MHC molecule with an open and empty groove. PLoS Biol. 3:e2577
60. Tada T, Ohkubo I, Niwa M, Sasaki M, Tateyama H, Eimoto T. 1991. Immunohistochemical localization of Zn-α2-glycoprotein in normal human tissues. J. Histochem. Cytochem. 39:1221-266
61. Hirai K, HusseyHJ, Barber MD, Price SA, Tisdale MJ. 1998. Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients. Cancer Res. 58:2359-655
62. Todorov PT, McDevitt TM, Meyer DJ, Ueyama H, Ohkubo I, Tisdale MJ. 1998. Purification and characterization of a tumor lipid-mobilizing factor. Cancer Res. 58:2353-588
63. Sanchez LM, Chirino AJ, Bjorkman P. 1999. Crystal structure of human ZAG, a fat-depleting factor related to MHC molecules. Science 283:1914-199
64. Delker SL, West AP Jr, McDermott L, Kennedy MW, Bjorkman PJ. 2004. Crystallographic studies of ligand binding by Zn-α2-glycoprotein. J. Struct. Biol. 148:205-133
65. McDermott LC, Freel JA, West AP, Bjorkman PJ, Kennedy MW. 2006. Zn-α2-glycoprotein, an MHC class I-related glycoprotein regulator of adipose tissues: modification or abrogation of ligand binding by site-directed mutagenesis. Biochemistry 45:2035-411
66. Russell ST, Tisdale MJ. 2012. Role ofβ-adrenergic receptors in the anti-obesity and anti-diabetic effects of zinc-α2-glycoprotien (ZAG). Biochim. Biophys. Acta 1821:590-999
67. Rolli V, RadosavljevicM, Astier V, Macquin C, Castan-Laurell I, et al. 2007. Lipolysis is altered inMHC class I zinc-α(2)-glycoprotein deficient mice. FEBS Lett. 581:394-4000
68. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, et al. 1996. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat. Genet. 13:399-4088
69. Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJ. 1997. Global prevalence of putative haemochromatosis mutations. J. Med. Genet. 34:275-788
70. Feder JN, Penny DM, Irrinki A, Lee VK, Lebron JA, et al. 1998. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc. Natl. Acad. Sci. USA 95:1472-777
71. Parkkila S, Waheed A, Britton RS, Bacon BR, Zhou XY, et al. 1997. Association of the transferrin receptor in human placenta with HFE, the protein defective in hereditary hemochromatosis. Proc. Natl. Acad. Sci. USA 94:13198-2022
72. Lebron JA, Bennett MJ, Vaughn DE, Chirino AJ, Snow PM, et al. 1998. Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor. Cell 93:111-233
73. Bennett MJ, Lebron JA, Bjorkman PJ. 2000. Crystal structure of the hereditary haemochromatosis protein HFE complexed with transferrin receptor. Nature 403:46-533
74. Ganz T. 2008. Iron homeostasis: fitting the puzzle pieces together. Cell Metab. 7:288-900
75. Rohrlich PS, Fazilleau N, Ginhoux F, Firat H, Michel F, et al. 2005. Direct recognition by αβcytolytic T cells of Hfe, aMHC class Ib molecule without antigen-presenting function. Proc. Natl. Acad. Sci. USA 102:12855-600
76. BouchermaR, Kridane-Miledi H, Vives FL, VauchyC, BorgC, et al. 2012. Loss of central and peripheral CD8-T-cell tolerance to HFE in mouse models of human familial hemochromatosis. Eur. J. Immunol. 42:851-622
77. Simister NE, Mostov KE. 1989. An Fc receptor structurally related to MHC class I antigens. Nature 337:184-877
78. Simister NE, Rees AR. 1985. Isolation and characterization of an Fc receptor from neonatal rat small intestine. Eur. J. Immunol. 15:733-388
79. Baker K, Qiao SW, Kuo T, Kobayashi K, Yoshida M, et al. 2009. Immune and non-immune functions of the (not so) neonatal Fc receptor, FcRn. Semin. Immunopathol. 31:223-366
80. Kuo TT, Baker K, Yoshida M, Qiao SW, Aveson VG, et al. 2010. Neonatal Fc receptor: from immunity to therapeutics. J. Clin. Immunol. 30:777-899
81. Qiao SW, Kobayashi K, Johansen FE, Sollid LM, Andersen JT, et al. 2008. Dependence of antibodymediated presentation of antigen on FcRn. Proc. Natl. Acad. Sci. USA 105:9337-422
82. ChaudhuryC, Mehnaz S, Robinson JM, HaytonWL, PearlDK, et al. 2003. Themajor histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J. Exp. Med. 197:315-222
83. Kobayashi K, Qiao SW, Yoshida M, Baker K, LencerWI, Blumberg RS. 2009. An FcRn-dependent role for anti-flagellin immunoglobulin G in pathogenesis of colitis in mice. Gastroenterology 137:1746-56.e11
84. Burmeister WP, Gastinel LN, Simister NE, Blum ML, Bjorkman PJ. 1994. Crystal structure at 2.2 ̊A resolution of the MHC-related neonatal Fc receptor. Nature 372:336-433
85. Burmeister WP, Huber AH, Bjorkman PJ. 1994. Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature 372:379-833
86. Martin WL, West AP Jr, Gan L, Bjorkman PJ. 2001. Crystal structure at 2.8 ̊A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol. Cell 7:867-777
87. Kasahara M, Yoshida S. 2012. Immunogenetics of the NKG2D ligand gene family. Immunogenetics 64:855-677
88. Rabinovich BA, Ketchem RR, WolfsonM, Goldstein L, Skelly M, CosmanD. 2008. A role for theMHC class I-like Mill molecules in nutrient metabolism and wound healing. Immunol. Cell Biol. 86:489-966
89. Bendelac A, Savage PB, Teyton L. 2007. The biology of NKT cells. Annu. Rev. Immunol. 25:297-3366
90. Brigl M, Brenner MB. 2004. CD1: antigen presentation and T cell function. Annu. Rev. Immunol. 22:817-900
91. Dascher CC. 2007. Evolutionary biology of CD1. Curr. Top. Microbiol. Immunol. 314:3-266
92. Porcelli S, Morita CT, BrennerMB. 1992. CD1b restricts the response of humanCD4-8-Tlymphocytes to a microbial antigen. Nature 360:593-977
93. Porcelli S, BrennerMB, Greenstein JL, Balk SP, Terhorst C, Bleicher PA. 1989. Recognition of cluster of differentiation 1 antigens by human CD4CD8 cytolytic T lymphocytes. Nature 341:447-500
94. Beckman EM, Porcelli SA, Morita CT, Behar SM, Furlong ST, Brenner MB. 1994. Recognition of a lipid antigen by CD1-restricted αβ+ T cells. Nature 372:691-944
95. Zeng Z, Castano AR, Segelke BW, Stura EA, Peterson PA, Wilson IA. 1997. Crystal structure of mouse CD1: an MHC-like fold with a large hydrophobic binding groove. Science 277:339-455
96. Bendelac A, Lantz O, Quimby ME, Yewdell JW, Bennink JR, Brutkiewicz RR. 1995. CD1 recognition by mouse NK1+ T lymphocytes. Science 268:863-655
97. Dougan SK, Kaser A, Blumberg RS. 2007. CD1 expression on antigen-presenting cells. Curr. Top. Microbiol. Immunol. 314:113-411
98. Barral DC, Brenner MB. 2007. CD1 antigen presentation: how it works. Nat. Rev. Immunol. 7:929-411
99. Salio M, Silk JD, Cerundolo V. 2010. Recent advances in processing and presentation of CD1 bound lipid antigens. Curr. Opin. Immunol. 22:81-888
100. De Libero G, Mori L. 2012. Novel insights into lipid antigen presentation. Trends Immunol. 33:103-111
101. Mori L, De Libero G. 2012. T cells specific for lipid antigens. Immunol. Res. 53:191-999
102. Moody DB, Young DC, Cheng TY, Rosat JP, Roura-Mir C, et al. 2004. T cell activation by lipopeptide antigens. Science 303:527-311
103. Moody DB, Ulrichs T, Muhlecker W, Young DC, Gurcha SS, et al. 2000. CD1c-mediated T-cell recognition of isoprenoid glycolipids in Mycobacterium tuberculosis infection. Nature 404:884-888
104. Kobayashi E, Motoki K, Uchida T, Fukushima H, Koezuka Y. 1995. KRN7000, a novel immunomodulator, and its antitumor activities. Oncol. Res. 7:529-344
105. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, et al. 1997. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science 278:1626-299
106. Kinjo Y, Wu D, Kim G, Xing GW, Poles MA, et al. 2005. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 434:520-255
107. Mattner J, Debord KL, Ismail N, Goff RD, Cantu C 3rd, et al. 2005. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 434:525-299
108. Kinjo Y, Tupin E, Wu D, Fujio M, Garcia-Navarro R, et al. 2006. Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat. Immunol. 7:978-866
109. Zajonc DM, Elsliger MA, Teyton L, Wilson IA. 2003. Crystal structure of CD1a in complex with a sulfatide self antigen at a resolution of 2.15 Å . Nat. Immunol. 4:808-155
110. Zajonc DM, Crispin MD, Bowden TA, Young DC, Cheng TY, et al. 2005. Molecular mechanism of lipopeptide presentation by CD1a. Immunity 22:209-199
111. Gadola SD, Zaccai NR, Harlos K, Shepherd D, Castro-Palomino JC, et al. 2002. Structure of human CD1b with bound ligands at 2.3 Å , a maze for alkyl chains. Nat. Immunol. 3:721-266
112. Batuwangala T, Shepherd D, Gadola SD, Gibson KJ, Zaccai NR, et al. 2004. The crystal structure of human CD1b with a bound bacterial glycolipid. J. Immunol. 172:2382-888
113. Scharf L, Li NS, Hawk AJ, Garzon D, ZhangT, et al. 2010. The 2.5 ̊A structure of CD1c in complex with a mycobacterial lipid reveals an open groove ideally suited for diverse antigen presentation. Immunity 33:853-622
114. Van Rhijn I, Young DC, De Jong A, Vazquez J, Cheng TY, et al. 2009. CD1c bypasses lysosomes to present a lipopeptide antigen with 12 amino acids. J. Exp. Med. 206:1409-222
115. Lopez-Sagaseta J, Sibener LV, Kung JE, Gumperz J, Adams EJ. 2012. Lysophospholipid presentation by CD1d and recognition by a human natural killer T-cell receptor. EMBO J. 31:2047-599
116. Koch M, Stronge VS, Shepherd D, Gadola SD, Mathew B, et al. 2005. The crystal structure of human CD1d with and without α-galactosylceramide. Nat. Immunol. 6:819-266
117. Garcia-Alles LF, Giacometti G, Versluis C, Maveyraud L, de Paepe D, et al. 2011. Crystal structure of human CD1e reveals a groove suited for lipid-exchange processes. Proc. Natl. Acad. Sci. USA 108:13230-355
118. de Lalla C, Lepore M, Piccolo FM, Rinaldi A, Scelfo A, et al. 2011. High-frequency and adaptive-like dynamics of human CD1 self-reactive T cells. Eur. J. Immunol. 41:602-100
119. de Jong A, Pena-Cruz V, Cheng TY, Clark RA, Van Rhijn I, Moody DB. 2010. CD1a-autoreactive T cells are a normal component of the human αβT cell repertoire. Nat. Immunol. 11:1102-99
120. Kasmar AG, van Rhijn I, Cheng TY, Turner M, Seshadri C, et al. 2011. CD1b tetramers bind αβ T cell receptors to identify a mycobacterial glycolipid-reactive T cell repertoire in humans. J. Exp. Med. 208:1741-477
121. Spada FM, Grant EP, Peters PJ, Sugita M, Melian A, et al. 2000. Self-recognition of CD1 by γ/δ T cells: implications for innate immunity. J. Exp. Med. 191:937-488
122. Shamshiev A, Gober HJ, Donda A, Mazorra Z, Mori L, De Libero G. 2002. Presentation of the same glycolipid by different CD1 molecules. J. Exp. Med. 195:1013-211
123. De Libero G, Moran AP, Gober HJ, Rossy E, Shamshiev A, et al. 2005. Bacterial infections promote T cell recognition of self-glycolipids. Immunity 22:763-722
124. Brennan PJ, Tatituri RV, Brigl M, Kim EY, Tuli A, et al. 2011. Invariant natural killer T cells recognize lipid self antigen induced by microbial danger signals. Nat. Immunol. 12:1202-111
125. Jahng A, Maricic I, Aguilera C, Cardell S, Halder RC, Kumar V. 2004. Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. J. Exp. Med. 199:947-577
126. Terabe M, Berzofsky JA. 2007. NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis. Trends Immunol. 28:491-966
127. Subramanian L, Blumenfeld H, Tohn R, Ly D, Aguilera C, et al. 2012. NKT cells stimulated by long fatty acyl chain sulfatides significantly reduces the incidence of type 1 diabetes in nonobese diabetic mice. PLoS ONE 7:e377711
128. Borg NA, Wun KS, Kjer-NielsenL, WilceMC, Pellicci DG, et al. 2007. CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature 448:44-499
129. Wun KS, Borg NA, Kjer-Nielsen L, Beddoe T, Koh R, et al. 2008. A minimal binding footprint on CD1d-glycolipid is a basis for selection of the unique human NKT TCR. J. Exp. Med. 205:939-499
130. Godfrey DI, Pellicci DG, Patel O, Kjer-Nielsen L, McCluskey J, Rossjohn J. 2010. Antigen recognition by CD1d-restricted NKT T cell receptors. Semin. Immunol. 22:61-677
131. Pellicci DG, Clarke AJ, Patel O, Mallevaey T, Beddoe T, et al. 2011. Recognition of β-linked self glycolipids mediated by natural killer T cell antigen receptors. Nat. Immunol. 12:827-333
132. Li Y, Girardi E, Wang J, Yu ED, Painter GF, et al. 2010. The Vα14 invariant natural killer T cell TCR forces microbial glycolipids and CD1d into a conserved binding mode. J. Exp. Med. 207:2383-933
133. Patel O, Pellicci DG, Gras S, Sandoval-Romero ML, Uldrich AP, et al. 2012. Recognition of CD1dsulfatide mediated by a type II natural killer T cell antigen receptor. Nat. Immunol. 13:857-633
134. Girardi E, Maricic I, Wang J, Mac TT, Iyer P, et al. 2012. Type II natural killer T cells use features of both innate-like and conventional T cells to recognize sulfatide self antigens. Nat. Immunol. 13:851-566
135. Oganesyan V, Oganesyan N, Terzyan S, Qu D, Dauter Z, et al. 2002. The crystal structure of the endothelial protein C receptor and a bound phospholipid. J. Biol. Chem. 277:24851-544
136. Lopez-Sagaseta J, Puy C, Tamayo I, Allende M, Cervero J, et al. 2012. sPLA2-V inhibits EPCR anticoagulant and antiapoptotic properties by accommodating lysophosphatidylcholine or PAF in the hydrophobic groove. Blood 119:2914-211
137. Willcox CR, Pitard V, Netzer S, Couzi L, Salim M, et al. 2012. Cytomegalovirus and tumor stress surveillance by binding of a human γδ T cell antigen receptor to endothelial protein C receptor. Nat. Immunol. 13:872-799
138. Raulet DH. 2003. Roles of the NKG2D immunoreceptor and its ligands. Nat. Rev. Immunol. 3:781-900
139. Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, et al. 2001. ULBPs, novel MHC class Irelated molecules, bind toCMVglycoproteinUL16 and stimulateNKcytotoxicity through theNKG2D receptor. Immunity 14:123-333
140. Champsaur M, Lanier LL. 2010. Effect of NKG2D ligand expression on host immune responses. Immunol. Rev. 235:267-855
141. Radaev S, Rostro B, Brooks AG, Colonna M, Sun PD. 2001. Conformational plasticity revealed by the cocrystal structure of NKG2D and its class I MHC-like ligand ULBP3. Immunity 15:1039-499
142. Li P, McDermottG, Strong RK. 2002. Crystal structures of RAE-1βand its complex with the activating immunoreceptor NKG2D. Immunity 16:77-866
143. Li P, Willie ST, Bauer S, Morris DL, Spies T, Strong RK. 1999. Crystal structure of the MHC class I homolog MIC-A, a γδT cell ligand. Immunity 10:577-844
144. Li P, Morris DL, Willcox BE, Steinle A, Spies T, Strong RK. 2001. Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA. Nat. Immunol. 2:443-511
145. Müller S, ZocherG, Steinle A, Stehle T. 2010. Structure of theHCMVUL16-MICB complex elucidates select binding of a viral immunoevasin to diverse NKG2D ligands. PLoS Pathog. 6:e10007233
146. Chalupny NJ, Rein-Weston A, Dosch S, Cosman D. 2006. Down-regulation of the NKG2D ligand MICA by the human cytomegalovirus glycoprotein UL142. Biochem. Biophys. Res. Commun. 346:175-811
147. Wills MR, Ashiru O, Reeves MB, Okecha G, Trowsdale J, et al. 2005. Human cytomegalovirus encodes an MHC class I-like molecule (UL142) that functions to inhibit NK cell lysis. J. Immunol. 175:7457-655
148. Steinle A, Li P, Morris DL, Groh V, Lanier LL, et al. 2001. Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family. Immunogenetics 53:279-877
149. McFarland BJ, Strong RK. 2003. Thermodynamic analysis of degenerate recognition by the NKG2D immunoreceptor: not induced fit but rigid adaptation. Immunity 19:803-122
150. McFarland BJ, Kortemme T, Yu SF, Baker D, Strong RK. 2003. Symmetry recognizing asymmetry: analysis of the interactions between the C-type lectin-like immunoreceptor NKG2D and MHC class I-like ligands. Structure 11:411-222
151. Spreu J, StehleT, Steinle A. 2006. Human cytomegalovirus-encodedUL16 discriminatesMIC molecules by their α2 domains. J. Immunol. 177:3143-499
152. Revilleza MJ, Wang R, Mans J, Hong M, Natarajan K, Margulies DH. 2011. How the virus outsmarts the host: function and structure of cytomegalovirusMHC- I-likemolecules in the evasion of natural killer cell surveillance. J. Biomed. Biotechnol. 2011:7246077
153. Cretney E, Degli-Esposti MA, Densley EH, Farrell HE, Davis-Poynter NJ, Smyth MJ. 1999. m144, a murine cytomegalovirus (MCMV)-encodedmajor histocompatibility complex class I homologue, confers tumor resistance to natural killer cell-mediated rejection. J. Exp. Med. 190:435-444
154. Yang Z, Bjorkman PJ. 2008. Structure of UL18, a peptide-binding viral MHC mimic, bound to a host inhibitory receptor. Proc. Natl. Acad. Sci. USA 105:10095-1000
155. Natarajan K, Hicks A, Mans J, Robinson H, Guan R, et al. 2006. Crystal structure of the murine cytomegalovirus MHC-I homolog m144. J. Mol. Biol. 358:157-711
156. Mans J, Natarajan K, Balbo A, Schuck P, Eikel D, et al. 2007. Cellular expression and crystal structure of the murine cytomegalovirusmajor histocompatibility complex class I-like glycoprotein, m153. J. Biol. Chem. 282:35247-588
157. Adams EJ, Juo ZS, Venook RT, Boulanger MJ, Arase H, et al. 2007. Structural elucidation of the m157 mouse cytomegalovirus ligand for Ly49 natural killer cell receptors. Proc. Natl. Acad. Sci. USA 104:10128-333
158. Samarakoon A, ChuH, Malarkannan S. 2009. MurineNKG2Dligands: "double, double toil and trouble." Mol. Immunol. 46:1011-199